Back to Studies P1111 / Safety, Tolerability and PK of Rilpivirine A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naïve HIV-1 Infected Children, < 12 Years of Age OverviewSitesProtocol Team Study Status Withdrawn DAIDS Number 11902 IND Number 119,735 Primary Protocol Team Members Ann Melvin Study Chair Ram Yogev Study Co-Chair Anne Coletti Clinical Research Manager Paul Sato DAIDS Medical Officer Ellen Townley DAIDS Medical Officer Stephen Spector Virologist Loading study documents... Loading study sites... Loading study protocol team... Loading study press... Loading study publications/presentations...